Affimed Logo
  • Science and Technology
    • ICE® (innate cell engager) Molecules
    • ROCK® Platform
    • Publications and Posters
  • Pipeline and Clinical Trials
  • About Us
    • Management Board
    • Supervisory Board
    • Scientific Advisory Board
    • Partners
  • News and Events
  • Innately Affimed
  • Investors
    • Webcasts and Corporate Presentation
    • Analyst Coverage
    • Share Information
    • SEC and Financial Reports
    • Corporate Governance Affimed
    • Annual General Meeting 2023
    • Sustainability Affimed
    • Press Release Distribution
  • Careers
    • Culture
  • Contact
Menu

News and Events

See what’s new at Affimed

News

All categories
Earnings
Press Release
All years
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress

November 14, 2023

Affimed Announces Acimtamig as International Nonproprietary Name for AFM13

November 9, 2023

Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023

November 7, 2023

Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

November 3, 2023

Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting

November 2, 2023

Affimed to Participate in Upcoming Investor Conferences

November 1, 2023

Affimed Announces Listing Transfer to Nasdaq Capital Markets

October 4, 2023

Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

September 27, 2023

Affimed to Present at the Cantor Global Healthcare Conference 2023

September 21, 2023

Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma

September 12, 2023

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31

Events

All
Scientific
Investors

09Dec

ASH Annual Meeting

December 9 - 12, 2023 (San Diego, USA)

WebcastsMore events

Affimed GmbH
Gottlieb-Daimler-Straße 2
68165 Mannheim
Germany

Phone: +49 (0)621-56003-0
Fax: +49 (0)621-56003-649
email hidden; JavaScript is required

  • Affimed Science and Technology
    • ICE® (innate cell engager) Molecules
    • ROCK® Platform
    • Publications and Posters
  • About Us
    • Management Board
    • Supervisory Board
    • Scientific Advisory Board
    • Partners
  • News and Events
  • Investors
    • Webcasts and Corporate Presentation
    • Analyst Coverage
    • Share Information
    • SEC and Financial Reports
    • Press Release Distribution
    • Corporate Governance
  • Careers
    • Culture

© 2023 Affimed GmbH

  • Data Protection
  • Imprint
  • Contact